Submit an Article
Navigate
Home
Editorial Board
Editorial Policies
Current Volume
Archive
Scientific Integrity
Publication Ethics Statements
Interviews with Outstanding Authors
Newsroom
Sponsored Conferences
Podcast
Contact
Special Collections
Submit an Article
Online ISSN: 1945-4589
Research Paper
|
Volume 12, Issue 24
|
pp. 25275–25293
DNA methylation-based lung adenocarcinoma subtypes can predict prognosis, recurrence, and immunotherapeutic implications
Back to article
Figure 8
(8 of 9)
−
100%
+
Figure 8.
Identification of novel candidate drugs targeting methylation signatures.
Figure 8 — DNA methylation-based lung adenocarcinoma subtypes can predict prognosis, recurrence, and immunotherapeutic implications | Aging
